Truist Financial Initiates Coverage on Altimmune (NASDAQ:ALT)

Research analysts at Truist Financial began coverage on shares of Altimmune (NASDAQ:ALT) in a research report issued on Wednesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Truist Financial’s price target would indicate a potential upside of 250.88% from the stock’s previous close.

ALT has been the subject of a number of other research reports. HC Wainwright lifted their price objective on shares of Altimmune from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Monday. Wall Street Zen cut shares of Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. B. Riley Financial lowered their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Finally, William Blair restated a “market perform” rating on shares of Altimmune in a research note on Thursday, March 5th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Altimmune currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Altimmune Stock Performance

NASDAQ ALT opened at $3.42 on Wednesday. Altimmune has a 12 month low of $2.90 and a 12 month high of $7.73. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15. The stock has a 50 day moving average of $4.45 and a 200-day moving average of $4.28. The company has a market cap of $444.94 million, a PE ratio of -3.39 and a beta of 0.13.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.00 million. On average, equities research analysts anticipate that Altimmune will post -1.35 EPS for the current fiscal year.

Insider Activity

In other Altimmune news, CEO Jerome Benedict Durso acquired 20,000 shares of the company’s stock in a transaction on Friday, March 6th. The stock was acquired at an average price of $3.54 per share, for a total transaction of $70,800.00. Following the purchase, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at $115,050. This trade represents a 160.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John Gill acquired 12,500 shares of the business’s stock in a transaction on Tuesday, December 23rd. The stock was acquired at an average cost of $4.10 per share, with a total value of $51,250.00. Following the acquisition, the director directly owned 12,500 shares in the company, valued at approximately $51,250. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 55,527 shares of company stock worth $213,778 over the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Altimmune by 23.3% in the third quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after buying an additional 1,206,514 shares during the period. State Street Corp grew its position in Altimmune by 42.2% during the fourth quarter. State Street Corp now owns 5,119,703 shares of the company’s stock worth $18,482,000 after buying an additional 1,518,448 shares in the last quarter. Geode Capital Management LLC increased its stake in Altimmune by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 2,292,410 shares of the company’s stock worth $8,278,000 after acquiring an additional 275,025 shares during the period. Two Sigma Investments LP increased its stake in Altimmune by 356.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock worth $7,528,000 after acquiring an additional 1,559,562 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in Altimmune by 140.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,349,293 shares of the company’s stock valued at $4,871,000 after acquiring an additional 787,036 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Altimmune

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Truist initiated coverage with a “Buy” rating and a $12.00 price target (roughly 250% upside vs. recent levels), which can attract new buyer interest and boost sentiment. Read More.
• Positive Sentiment: HC Wainwright reiterated a “Buy” stance and maintained a very high $25.00 target while raising several near‑term EPS forecasts (Q1–Q4 2026 and FY2026/FY2027 improvements), signaling better near‑term operating expectations and providing a bullish research narrative for investors. Read More.
• Neutral Sentiment: Short‑interest data published for March shows “0 shares” and NaN changes (days‑to‑cover reported as 0.0), which appears to be a reporting error. Because the numbers are unreliable, they are unlikely to be a meaningful trading signal until corrected.
• Neutral Sentiment: Multiple HC Wainwright model updates were issued: while near‑term quarterly and FY2026/FY2027 EPS forecasts were raised (positive), the firm also repriced longer‑range forecasts — creating mixed signals that may keep momentum uneven. Read More.
• Negative Sentiment: HC Wainwright trimmed FY2028 and FY2029 EPS estimates materially (FY2028 moved from ~(-$0.09) to about (-$1.19); FY2029 forecasts were cut sharply), reflecting weaker long‑range expectations that could limit upside beyond near‑term reactions. Read More.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.